This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Under the Radar: Owens & Minor Expands

"Under-the-Radar Stocks" is a daily feature that uncovers little-known companies worthy of investors' consideration. Check in at 5 every morning to find out about stocks that tend to beat their bigger brethren.

As the rally fizzles, defensive stocks are returning to the spotlight, especially health care. Here's a small-cap medical supply distributor poised to gain.

TheStreet.com Ratings

Owens & Minor (OMI - Get Report) has carved a niche by distributing other companies' medical products, everything from scrubs to scalpels. The company serves major players like Cardinal Health (CAH - Get Report) and Covidien (COV), and sells its own discount line of common medical products under the brand MediChoice. In August, the company acquired Burrows Co., a Chicago-based medical supplier, for $30.2 million to expand its reach.

Aging baby boomers will boost demand for health care supplies for years to come, increasing revenue for medical suppliers and manufacturers. In the past month, the Dow Jones U.S. Health Care Index, which includes Abbott Laboratories (ABT - Get Report), Amgen (AMGN - Get Report) and Johnson & Johnson (JNJ - Get Report), climbed 2% as the Dow Jones Industrial Average lost 6.1%.

First-quarter revenue at the Richmond, Va.-based company rose 13% to $1.9 billion. Net income dropped 42% to $14 million because of the cost of divesting a direct-to-consumer diabetes-supply business. Earnings per share from continuing operations fell 8.5% to 54 cents.

The company's operating margin has shed 46 basis points to a slim 2% since the year-earlier quarter as the net margin shrank by half to 0.7%.

Owens & Minor's strong balance sheet compensates for its weak profitability. The company has quadrupled its cash position to $11 million since last year's first quarter. A debt-to-equity ratio of 0.31 reflects its conservative approach.

We rate the company "buy" with a financial strength score of 7.9 out of 10, better than the 7 average of our "buy"-rated stocks.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
COV $106.71 -1.26%
ABT $47.37 0.00%
AMGN $157.72 0.00%
CAH $87.99 0.00%
JNJ $102.51 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs